Pharmacogenomic Testing for Cancer

Overseen By Alicia Patrick

Age: 18+

Sex: Any

Trial Phase: Academic

Sponsor: Wake Forest University Health Sciences

Must be taking: Fluoropyrimidines

Disqualifiers: Prior transplants, others

No Placebo Group All trial participants will receive the active study treatment (no placebo)

Compensation: Varies

Number of Visits: Unknown

120 Participants Needed

Trial Summary

What is the purpose of this trial?

The purpose of this research is to evaluate the impact of a microarray PGx test on prescribing/dosing of drugs and cancer treatments in patients with cancer who are currently eligible for single-gene DPYD testing.

Research Team

Jai Patel, PharmD

Principal Investigator

Atrium Health Levine Cancer

Eligibility Criteria

This trial is for cancer patients eligible for DPYD gene testing, which helps tailor drug dosing. Specifics about who can join are not provided, but typically participants have a certain type of cancer and meet other health standards.

Inclusion Criteria

Written informed consent and HIPAA authorization for release of personal health information

I am set to receive or am currently on a chemotherapy that requires DPYD gene testing.

I am willing to give more cheek swabs if needed for DNA testing.

Exclusion Criteria

I have had a bone marrow or liver transplant in the past.

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Pharmacogenomic Testing

A pharmacogenomic (PGx) microarray panel is performed to test for genetic variations in genes related to drug response

1 week

Follow-up

Participants are monitored for safety and effectiveness after receiving the microarray profiling results

6 months

Treatment Details

Interventions

• Global Diversity Array with Enhanced PGx

Trial Overview The study tests the 'Global Diversity Array with Enhanced PGx' microarray to see if it affects how doctors prescribe and dose cancer treatments compared to current single-gene testing methods.

Participant Groups

Group I: Pharmacogenomic Testing Experimental Treatment 1 Intervention

A pharmacogenomic (PGx) microarray (multi-gene) panel will be performed to test for genetic variations in genes related to drug response.

Who Is Running the Clinical Trial?

Wake Forest University Health Sciences

Lead Sponsor

Trials

1,432

Recruited

2,506,000+

Atrium Health Levine Cancer Institute

Collaborator

Trials

30

Recruited

4,700+